The recognition of TK dysregulation as a key driver in NSCLC has led to the development of tyrosine kinase inhibitors (TKIs), which have significantly improved patient outcomes, particularly in cases with EGFR mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.